Article ; Online: Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
2024
Abstract: Sézary syndrome is an aggressive leukemic expansion of skin derived malignant CD4+ T cells. Drug ... monotherapy often results in disease relapse due to the heterogenous nature of malignant CD4+ T cells, but how ... peripheral CD4+ T cells acquired a distinct profile of transcription factors and trafficking receptors ...
| Abstract | Sézary syndrome is an aggressive leukemic expansion of skin derived malignant CD4+ T cells. Drug monotherapy often results in disease relapse due to the heterogenous nature of malignant CD4+ T cells, but how therapies can be optimally combined remains unclear due to limitations in understanding the disease pathogenesis. We identified immunologic transitions that interlink mycosis fungoides (MF) with Sézary syndrome (SS) using single-cell transcriptome analysis in parallel with high-throughput TCR sequencing. Nascent peripheral CD4+ T cells acquired a distinct profile of transcription factors and trafficking receptors that gave rise to antigenically mature Sézary cells. The emergence of malignant CD4+ T cells coincided with the accumulation of dysfunctional monocytes with impaired Fc-dependent phagocytosis, decreased responsiveness to cytokine stimulation and limited repertoire of intercellular interactions with Sézary cells. Type I interferon supplementation when combined with a monoclonal antibody targeting the chemokine receptor type 4 (CCR4), unleashed monocyte induced phagocytosis and eradication of Sézary cells in vitro. In turn, co-administration of interferon- with the FDA-approved anti-CCR4 antibody, mogamulizumab, in patients with SS induced marked depletion of peripheral malignant CD4+ T cells. Importantly, residual CD4+ T cells following Sézary cell ablation lacked any immunologic shifts. These findings collectively unveil an auxiliary role for augmenting monocytic activity during mogamulizumab therapy in the treatment of SS and underscore the importance of targeted combination therapy in this disease. |
|---|---|
| Language | English |
| Publishing date | 2024-03-15 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2915908-8 |
| ISSN | 2473-9537 ; 2473-9529 |
| ISSN (online) | 2473-9537 |
| ISSN | 2473-9529 |
| DOI | 10.1182/bloodadvances.2023010043 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 7153: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.